ゼリア新薬工業の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/03/21 | 2,212 | 2,213 | 2,183 | 2,189 | -8 | -0.4% | 87,500 |
2024/03/19 | 2,181 | 2,200 | 2,176 | 2,197 | +10 | +0.5% | 46,600 |
2024/03/18 | 2,176 | 2,194 | 2,170 | 2,187 | +6 | +0.3% | 92,200 |
2024/03/15 | 2,124 | 2,192 | 2,124 | 2,181 | +57 | +2.7% | 138,600 |
2024/03/14 | 2,119 | 2,129 | 2,102 | 2,124 | +16 | +0.8% | 44,100 |
2024/03/13 | 2,122 | 2,128 | 2,099 | 2,108 | -14 | -0.7% | 46,100 |
2024/03/12 | 2,134 | 2,134 | 2,090 | 2,122 | -12 | -0.6% | 48,600 |
2024/03/11 | 2,138 | 2,149 | 2,108 | 2,134 | -20 | -0.9% | 70,500 |
2024/03/08 | 2,137 | 2,167 | 2,123 | 2,154 | +15 | +0.7% | 83,900 |
2024/03/07 | 2,172 | 2,172 | 2,131 | 2,139 | -14 | -0.7% | 57,400 |
2024/03/06 | 2,115 | 2,168 | 2,115 | 2,153 | +34 | +1.6% | 125,200 |
2024/03/05 | 2,144 | 2,144 | 2,107 | 2,119 | -28 | -1.3% | 53,700 |
2024/03/04 | 2,144 | 2,169 | 2,125 | 2,147 | +30 | +1.4% | 98,100 |
2024/03/01 | 2,125 | 2,130 | 2,107 | 2,117 | -3 | -0.1% | 38,500 |
2024/02/29 | 2,127 | 2,127 | 2,108 | 2,120 | +6 | +0.3% | 55,500 |
2024/02/28 | 2,130 | 2,141 | 2,111 | 2,114 | -17 | -0.8% | 48,200 |
2024/02/27 | 2,145 | 2,147 | 2,125 | 2,131 | -18 | -0.8% | 41,300 |
2024/02/26 | 2,145 | 2,166 | 2,140 | 2,149 | ±0 | ±0% | 61,700 |
2024/02/22 | 2,176 | 2,176 | 2,138 | 2,149 | -6 | -0.3% | 69,100 |
2024/02/21 | 2,178 | 2,180 | 2,152 | 2,155 | -23 | -1.1% | 45,000 |
2024/02/20 | 2,178 | 2,192 | 2,172 | 2,178 | +5 | +0.2% | 41,700 |
2024/02/19 | 2,175 | 2,176 | 2,159 | 2,173 | +8 | +0.4% | 37,100 |
2024/02/16 | 2,162 | 2,174 | 2,139 | 2,165 | +35 | +1.6% | 62,800 |
2024/02/15 | 2,143 | 2,150 | 2,108 | 2,130 | -13 | -0.6% | 66,200 |
2024/02/14 | 2,182 | 2,182 | 2,128 | 2,143 | -39 | -1.8% | 71,500 |
2024/02/13 | 2,171 | 2,188 | 2,156 | 2,182 | +17 | +0.8% | 79,600 |
2024/02/09 | 2,180 | 2,191 | 2,150 | 2,165 | -31 | -1.4% | 85,200 |
2024/02/08 | 2,211 | 2,211 | 2,172 | 2,196 | -15 | -0.7% | 83,900 |
2024/02/07 | 2,185 | 2,211 | 2,177 | 2,211 | +25 | +1.1% | 100,500 |
2024/02/06 | 2,258 | 2,264 | 2,185 | 2,186 | -77 | -3.4% | 163,600 |
2024/02/05 | 2,146 | 2,263 | 2,126 | 2,263 | +67 | +3.1% | 287,700 |
2024/02/02 | 2,261 | 2,270 | 2,186 | 2,196 | +154 | +7.5% | 588,000 |
2024/02/01 | 2,040 | 2,048 | 2,018 | 2,042 | -9 | -0.4% | 97,900 |
2024/01/31 | 2,026 | 2,051 | 2,024 | 2,051 | +18 | +0.9% | 47,000 |
2024/01/30 | 2,050 | 2,056 | 2,033 | 2,033 | -12 | -0.6% | 52,700 |
2024/01/29 | 2,031 | 2,046 | 2,031 | 2,045 | +17 | +0.8% | 40,300 |
2024/01/26 | 2,030 | 2,041 | 2,020 | 2,028 | -5 | -0.2% | 57,600 |
2024/01/25 | 2,020 | 2,034 | 2,019 | 2,033 | +15 | +0.7% | 51,000 |
2024/01/24 | 2,029 | 2,031 | 2,004 | 2,018 | -11 | -0.5% | 57,500 |
2024/01/23 | 2,026 | 2,048 | 2,025 | 2,029 | -1 | ±0% | 64,000 |
2024/01/22 | 2,023 | 2,035 | 2,023 | 2,030 | +9 | +0.4% | 39,100 |
2024/01/19 | 2,032 | 2,037 | 2,014 | 2,021 | -24 | -1.2% | 79,000 |
2024/01/18 | 2,040 | 2,048 | 2,030 | 2,045 | -2 | -0.1% | 51,500 |
2024/01/17 | 2,074 | 2,079 | 2,047 | 2,047 | -15 | -0.7% | 56,900 |
2024/01/16 | 2,080 | 2,083 | 2,061 | 2,062 | -16 | -0.8% | 43,400 |
2024/01/15 | 2,063 | 2,078 | 2,052 | 2,078 | +19 | +0.9% | 50,600 |
2024/01/12 | 2,070 | 2,074 | 2,050 | 2,059 | +5 | +0.2% | 65,200 |
2024/01/11 | 2,070 | 2,072 | 2,050 | 2,054 | -9 | -0.4% | 72,500 |
2024/01/10 | 2,050 | 2,073 | 2,040 | 2,063 | +16 | +0.8% | 67,300 |
2024/01/09 | 2,053 | 2,058 | 2,034 | 2,047 | +14 | +0.7% | 50,400 |
351~
400
件表示中 / 3769件
類似銘柄と比較する
現在ご覧いただいている「ゼリア新薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
ゼリア新薬 | 206,000円 | +3.1% | -6.5% | 2.33% | 9.56倍 | 1.01倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ジーエヌアイ | 274,000円 | +21.7% | +999.9% | 0.00% | 12.62倍 | 4.32倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
持田薬 | 318,500円 | +5.1% | -7.0% | 2.51% | 20.91倍 | 0.86倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
杏林製薬 | 154,600円 | -2.4% | -52.3% | 3.69% | 18.50倍 | 0.65倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
栄研化 | 238,900円 | +4.1% | -3.1% | 2.43% | 20.75倍 | 1.81倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム